SOURCE: BioMedReports


September 06, 2012 08:28 ET

Report Focuses on NovaBay Pharmaceuticals' Diverse Pipeline and Multiple Upcoming Catalysts

LOS ANGELES, CA--(Marketwire - Sep 6, 2012) - A new detailed report focused on NovaBay Pharmaceuticals (NYSE MKT: NBY) by biotech columnist Scott Matusow sheds light on the big board listed, emerging biotech firm which is developing two distinct anti-infective product lines led by NVC-422 and NeutroPhase R -- also referred to as NVC-101.

Both compounds are designed to work by mimicking the body's natural defense against infection and because the immune system works without ever creating resistance, NovaBay has taken the effective and rapidly acting molecules that function within the body and created stable analogs of these molecules.

Currently the landscape for anti-bacterial drugs to treat skin infections is dominated by big players like Pfizer -- which has two drugs that combine for over 1.5 billion in worldwide sales. Forest Labs is also trying to increase market share in this area with an injectable drug called Teflaro, which the company expects to sell $65 million worth of this in 2012. NovaBay differentiates itself with a unique way of treating the bacteria.

After a detailed examination of the firm's catalysts and pipeline, Matusow believes a market capitalization of $120M-$150M is more appropriate for NovaBay, He issues a price target opinion between $3.50 and $4.00 a share in the next 6 months for the firm.

The full detailed report on NBY is available at:

Healthcare investors and Biotech traders interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades and see upcoming catalysts can go to:

News developments and live healthcare sector updates are available constantly via twitter at:

About BioMedReports.Com

BioMedReports is a news and research portal covering financial biomedical news and the entire Healthcare Sector of the market. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies. They sell a premium product for subscribers and full disclosures and information about the stocks and news mentioned in this news release is available at BioMedReports.Com

Contact Information

  • Media Contacts Only:
    Mary Davila
    Assistant Editor
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556